Literature DB >> 23453578

The mechanism of differential neutralization of dengue serotype 3 strains by monoclonal antibody 8A1.

Yang Zhou1, S Kyle Austin, Daved H Fremont, Boyd L Yount, Jeremy P Huynh, Aravinda M de Silva, Ralph S Baric, William B Messer.   

Abstract

While previous studies have demonstrated that envelope (E) glycoprotein variation between dengue viruses (DENV) genotypes can influence antibody neutralization potency, the mechanisms of variable neutralization remain incompletely understood. Here we characterize epitope antibody interactions of a DENV-3 EDIII binding mouse mAb 8A1 which displays highly variable neutralizing activity against DENV-3 genotypes. Using a DENV-3 reverse genetics platform, we characterize ability of 8A1 to bind and neutralize naturally occurring DENV-3 E genotypic variant viruses. Introduction of single and multiple amino acid mutations into the parental clone background demonstrates that mutations at positions 301 and 383 on EDIII are responsible for 8A1 differential neutralization phenotypes. ELISA and surface plasmon resonance (SPR) studies indicate differences in binding are responsible for the variable neutralization. Variability at position 301 primarily determined binding difference through influencing antibody-EDIII dissociation rate. Our findings are relevant to many groups focusing on DENV EDIII as a vaccine target.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23453578      PMCID: PMC3608513          DOI: 10.1016/j.virol.2013.01.022

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  39 in total

1.  Monoclonal antibodies that bind to domain III of dengue virus E glycoprotein are the most efficient blockers of virus adsorption to Vero cells.

Authors:  W D Crill; J T Roehrig
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

2.  Binding of a neutralizing antibody to dengue virus alters the arrangement of surface glycoproteins.

Authors:  Shee-Mei Lok; Victor Kostyuchenko; Grant E Nybakken; Heather A Holdaway; Anthony J Battisti; Soila Sukupolvi-Petty; Dagmar Sedlak; Daved H Fremont; Paul R Chipman; John T Roehrig; Michael S Diamond; Richard J Kuhn; Michael G Rossmann
Journal:  Nat Struct Mol Biol       Date:  2008-02-10       Impact factor: 15.369

3.  Diversity and junction residues as hotspots of binding energy in an antibody neutralizing the dengue virus.

Authors:  Hugues Bedouelle; Laurent Belkadi; Patrick England; J Iñaki Guijarro; Olesia Lisova; Agathe Urvoas; Muriel Delepierre; Philippe Thullier
Journal:  FEBS J       Date:  2006-01       Impact factor: 5.542

Review 4.  Molecular mechanisms of antibody-mediated neutralisation of flavivirus infection.

Authors:  Theodore C Pierson; Michael S Diamond
Journal:  Expert Rev Mol Med       Date:  2008-05-12       Impact factor: 5.600

5.  The envelope glycoprotein from tick-borne encephalitis virus at 2 A resolution.

Authors:  F A Rey; F X Heinz; C Mandl; C Kunz; S C Harrison
Journal:  Nature       Date:  1995-05-25       Impact factor: 49.962

6.  Characterization of an antigenic site that contains a dominant, type-specific neutralization determinant on the envelope protein domain III (ED3) of dengue 2 virus.

Authors:  Gregory D Gromowski; Alan D T Barrett
Journal:  Virology       Date:  2007-08-23       Impact factor: 3.616

7.  The stoichiometry of antibody-mediated neutralization and enhancement of West Nile virus infection.

Authors:  Theodore C Pierson; Qing Xu; Steevenson Nelson; Theodore Oliphant; Grant E Nybakken; Daved H Fremont; Michael S Diamond
Journal:  Cell Host Microbe       Date:  2007-04-19       Impact factor: 21.023

8.  Mapping to completeness and transplantation of a group-specific, discontinuous, neutralizing epitope in the envelope protein of dengue virus.

Authors:  Olesia Lisova; Florence Hardy; Vincent Petit; Hugues Bedouelle
Journal:  J Gen Virol       Date:  2007-09       Impact factor: 3.891

9.  Antibody neutralization and viral virulence in recurring dengue virus type 2 outbreaks.

Authors:  Sook-San Wong; Juraina Abd-Jamil; Sazaly Abubakar
Journal:  Viral Immunol       Date:  2007-09       Impact factor: 2.257

10.  Co-circulation of two genotypes of dengue virus serotype 3 in Guangzhou, China, 2009.

Authors:  Tao Jiang; Xue-Dong Yu; Wen-Xin Hong; Wei-Ze Zhou; Man Yu; Yong-Qiang Deng; Shun-Ya Zhu; E-De Qin; Jian Wang; Cheng-Feng Qin; Fu-Chun Zhang
Journal:  Virol J       Date:  2012-06-22       Impact factor: 4.099

View more
  9 in total

1.  Generation and Characterization of Antinonstructural Protein 1 Monoclonal Antibodies and Development of Diagnostics for Dengue Virus Serotype 2.

Authors:  Yin-Liang Tang; I-Ju Liu; Pi-Chun Li; Chien-Yu Chiu; Chun-Yu Lin; Chung-Hao Huang; Yen-Hsu Chen; Chi-Yu Fu; Day-Yu Chao; Chwan-Chuen King; Han-Chung Wu
Journal:  Am J Trop Med Hyg       Date:  2017-07-27       Impact factor: 2.345

2.  Precisely Molded Nanoparticle Displaying DENV-E Proteins Induces Robust Serotype-Specific Neutralizing Antibody Responses.

Authors:  Stefan W Metz; Shaomin Tian; Gabriel Hoekstra; Xianwen Yi; Michelle Stone; Katie Horvath; Michael J Miley; Joseph DeSimone; Chris J Luft; Aravinda M de Silva
Journal:  PLoS Negl Trop Dis       Date:  2016-10-20

3.  Protective Capacity of the Human Anamnestic Antibody Response during Acute Dengue Virus Infection.

Authors:  Meihui Xu; Roland Züst; Ying Xiu Toh; Jennifer M Pfaff; Kristen M Kahle; Edgar Davidson; Benjamin J Doranz; Sumathy Velumani; Farhana Tukijan; Cheng-I Wang; Katja Fink
Journal:  J Virol       Date:  2016-11-28       Impact factor: 5.103

4.  Oligomeric state of the ZIKV E protein defines protective immune responses.

Authors:  Stefan W Metz; Ashlie Thomas; Alex Brackbill; John Forsberg; Michael J Miley; Cesar A Lopez; Helen M Lazear; Shaomin Tian; Aravinda M de Silva
Journal:  Nat Commun       Date:  2019-10-10       Impact factor: 14.919

5.  Immune profile and responses of a novel dengue DNA vaccine encoding an EDIII-NS1 consensus design based on Indo-African sequences.

Authors:  Arun Sankaradoss; Suraj Jagtap; Junaid Nazir; Shefta E Moula; Ayan Modak; Joshuah Fialho; Meenakshi Iyer; Jayanthi S Shastri; Mary Dias; Ravisekhar Gadepalli; Alisha Aggarwal; Manoj Vedpathak; Sachee Agrawal; Awadhesh Pandit; Amul Nisheetha; Anuj Kumar; Mahasweta Bordoloi; Mohamed Shafi; Bhagyashree Shelar; Swathi S Balachandra; Tina Damodar; Moses Muia Masika; Patrick Mwaura; Omu Anzala; Kar Muthumani; Ramanathan Sowdhamini; Guruprasad R Medigeshi; Rahul Roy; Chitra Pattabiraman; Sudhir Krishna; Easwaran Sreekumar
Journal:  Mol Ther       Date:  2022-01-07       Impact factor: 12.910

Review 6.  Morphological Diversity and Dynamics of Dengue Virus Affecting Antigenicity.

Authors:  Guntur Fibriansah; Xin-Ni Lim; Shee-Mei Lok
Journal:  Viruses       Date:  2021-07-24       Impact factor: 5.048

7.  Analysis of Neutralizing Antibodies as a Correlate of Instantaneous Risk of Hospitalized Dengue in Placebo Recipients of Dengue Vaccine Efficacy Trials.

Authors:  Ying Huang; Brian D Williamson; Zoe Moodie; Lindsay N Carpp; Laurent Chambonneau; Carlos A DiazGranados; Peter B Gilbert
Journal:  J Infect Dis       Date:  2022-01-18       Impact factor: 7.759

8.  Dengue virus-like particles mimic the antigenic properties of the infectious dengue virus envelope.

Authors:  Stefan W Metz; Ashlie Thomas; Laura White; Mark Stoops; Markus Corten; Holger Hannemann; Aravinda M de Silva
Journal:  Virol J       Date:  2018-04-02       Impact factor: 4.099

9.  Nanoparticle delivery of a tetravalent E protein subunit vaccine induces balanced, type-specific neutralizing antibodies to each dengue virus serotype.

Authors:  Stefan W Metz; Ashlie Thomas; Alex Brackbill; Yi Xianwen; Michele Stone; Katie Horvath; Michael J Miley; Chris Luft; Joseph M DeSimone; Shaomin Tian; Aravinda M de Silva
Journal:  PLoS Negl Trop Dis       Date:  2018-09-24
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.